SCHEMBL78986

SCHEMBL78986

Cc1cnc(N)c(C)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29512993 1.00
Fluoride Ion SCHEMBL28306558 0.95 NOS3 (0.38)
SCHEMBL12648083 0.81
SCHEMBL30716708 0.81
SCHEMBL10255501 0.79
SCHEMBL30828998 0.79
SCHEMBL259696 0.79
SCHEMBL1255045 0.77
SCHEMBL30423024 0.77
SCHEMBL13354601 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016040780-A1 AMINOMETHYL- AND METHYLOXY-LINKED TRICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN AGGREGATION NEUROPORE THERAPIES, INC. (US) 2016-03-17 WO claimed
EP-2685821-A1 NUCLEAR HORMONE RECEPTOR MODULATORS AbbVie Inc. (US) 2014-01-22 EP claimed
US-20120238549-A1 Nuclear Hormone Receptor Modulators ABBOTT LABORATORIES (US) 2012-09-20 US claimed
WO-2012125797-A1 NUCLEAR HORMONE RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2012-09-20 WO claimed
CN-102056927-A Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors IRM LLC 2011-05-11 CN claimed
EP-0175263-B1 2-AMINO-3-CHLOROMETHYL-5-(DICHLOROMETHYL)-PYRAZINES AND PROCESS FOR THEIR PREPARATION BASF Aktiengesellschaft (DE) 1991-06-05 EP claimed
EP-0175263-A2 2-Amino-3-chloromethyl-5-(dichloromethyl)-pyrazines and process for their preparation BASF Aktiengesellschaft (DE) 1986-03-26 EP claimed
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use AMGEN INC. (US) 2025-11-18 US disclosed
US-12384789-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2025-08-12 US disclosed
US-12139499-B2 Heteroaryl compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2024-11-12 US disclosed
EP-3814360-B1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2024-10-02 EP disclosed
EP-3814345-B1 HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2024-09-25 EP disclosed
US-12036292-B2 Heterobiaryl compounds and imaging agents for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2024-07-16 US disclosed
EP-0111160-B1 PROCESS FOR THE PREPARATION OF 2-HALOGEN AND 2-CYANO PYRAZINES BASF Aktiengesellschaft (DE) 1986-10-22 EP disclosed
EP-0175264-A2 Process for the preparation of 2-amino-3-cyano-5-dialkoxymethyl pyrazines and intermediates for this process BASF Aktiengesellschaft (DE) 1986-03-26 EP disclosed
EP-0175263-A2 2-Amino-3-chloromethyl-5-(dichloromethyl)-pyrazines and process for their preparation BASF Aktiengesellschaft (DE) 1986-03-26 EP disclosed
EP-0175263-A2 2-Amino-3-chloromethyl-5-(dichloromethyl)-pyrazines and process for their preparation BASF Aktiengesellschaft (DE) 1986-03-26 EP disclosed
US-4560756-A 2-Aminopyrazines and the preparation of 2-aminopyrazines and pyrazines BASF AKTIENGESELLSCHAFT (DE) 1985-12-24 US disclosed
EP-0111717-A2 2-Aminopyrazine and process for the preparation of 2-aminopyrazines and pyrazines BASF Aktiengesellschaft (DE) 1984-06-27 EP disclosed
EP-0111160-A1 Process for the preparation of 2-halogen and 2-cyano pyrazines BASF Aktiengesellschaft (DE) 1984-06-20 EP disclosed